Vistagen Therapeutics logo

Vistagen Therapeutics Share Price Today (NASDAQ: VTGN)

Vistagen Therapeutics share price is $2.01 & ₹172.23 as on 1 Jul 2025, 01.30 'hrs' IST

$2.01

0.04

(2.03%)

Market is closed - opens 7 PM, 01 Jul 2025

View live Vistagen Therapeutics share price in Dollar and Rupees. Guide to invest in Vistagen Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Vistagen Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Vistagen Therapeutics share price movements

  • Today's Low: $2.00
    Today's High: $2.07

    Day's Volatility :3.38%

  • 52 Weeks Low: $1.90
    52 Weeks High: $4.21

    52 Weeks Volatility :54.87%

Vistagen Therapeutics (VTGN) Returns

PeriodVistagen Therapeutics IncIndex (Russel 2000)
3 Months
-15.81%
0.0%
6 Months
-33.22%
0.0%
1 Year
-44.82%
0.0%
3 Years
-92.5%
3.6%

Vistagen Therapeutics (VTGN) Key Statistics

in dollars & INR

Previous Close
$1.97
Open
$2.045
Today's High
$2.07
Today's Low
$2.0
Market Capitalization
$57.4M
Today's Volume
$222.3K
52 Week High
$4.21
52 Week Low
$1.9
Revenue TTM
$486.0K
EBITDA
$-55.8M
Earnings Per Share (EPS)
$-1.67
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-55.69%

How to invest in Vistagen Therapeutics Stock (VTGN) from India?

It is very easy for Indian residents to invest directly in Vistagen Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Vistagen Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Vistagen Therapeutics or VTGN on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Vistagen Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Vistagen Therapeutics shares which would translate to 0.426 fractional shares of Vistagen Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India , including recognised companies like Vistagen Therapeutics, in just a few clicks!

Returns in Vistagen Therapeutics (VTGN) for Indian investors in Rupees

The Vistagen Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Vistagen Therapeutics investment value today

Current value as on today

₹59,091

Returns

₹40,909

(-40.91%)

Returns from Vistagen Therapeutics Stock

₹43,697 (-43.7%)

Dollar Returns*

₹2,788 (+2.79%)

Indian investors sentiment towards Vistagen Therapeutics (VTGN)

117%

Period: May 31, 2025 to Jun 30, 2025. Change in 30 Days versus previous period

Search interest for Vistagen Therapeutics Stock from India on INDmoney has increased by 117% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Vistagen Therapeutics

  • TCG Crossover Management, LLC

    9.23%

  • StemPoint Capital LP

    8.16%

  • Nantahala Capital Management, LLC

    6.82%

  • Vanguard Group Inc

    6.76%

  • COMMODORE CAPITAL LP

    5.43%

  • Sphera Funds Management Ltd.

    2.73%

Analyst Recommendation on Vistagen Therapeutics

Rating
Trend

Buy

    90%Buy

    10%Hold

    0%Sell

Based on 10 Wall street analysts offering stock ratings for Vistagen Therapeutics(by analysts ranked 0 to 5 stars)

Analyst Forecast on Vistagen Therapeutics Stock (VTGN)

What analysts predicted

Upside of 546.77%

Target:

$13.00

Current:

$2.01

Insights on Vistagen Therapeutics Stock (Ticker Symbol: VTGN)

  • Price Movement

    In the last 1 month, VTGN stock has moved down by -23.6%
  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 234.0K → -15.0K (in $), with an average decrease of 106.4% per quarter
  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -14.08M → -13.63M (in $), with an average increase of 3.3% per quarter
  • VTGN vs ONC (1 yr)

    In the last 1 year, Beone Medicines Ltd has given 69.1% return, outperforming this stock by 112.5%
  • VTGN vs ALNY (3 yr)

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 49.0% return, outperforming this stock by 141.5%
  • Price to Sales

    ForVTGN every $1 of sales, investors are willing to pay $123.8, whereas for Beone Medicines Ltd, the investors are paying $6.1 for every $1 of sales.

Vistagen Therapeutics Technicals Summary

Sell

Neutral

Buy

Vistagen Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Vistagen Therapeutics (VTGN) Vs Peers

Returns
Ratio's
Overview
Company Name1 Month6 Month1 Year3 Years5 Years
Vistagen Therapeutics Inc logo
-18.76%
-33.22%
-44.82%
-92.5%
-87.63%
Regeneron Pharmaceuticals, Inc. logo
6.15%
-26.86%
-50.71%
-12.67%
-16.3%
Beone Medicines Ltd logo
-1.92%
30.58%
66.47%
24.02%
23.15%
Vertex Pharmaceuticals Incorporated logo
-0.93%
9.59%
-6.36%
52.71%
51.6%
Alnylam Pharmaceuticals, Inc. logo
5.47%
37.19%
32.68%
114.18%
115.41%

About Vistagen Therapeutics

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline comprises of Fasedienol(PH94B), an investigational pherine nasal spray for the treatment of anxiety in adults with social anxiety disorder which is in Phase III clinical trial; and Itruvone(PH10), an odorless synthetic investigational neuroactive pherine nasal spray for the treatment of major depressive disorder which is in Phase II clinical trial. It also develops PH80, an odorless and tasteless synthetic investigational pherine nasal spray with a novel for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women's health disorders that is in Phase II clinical trial; PH15, an investigational pherine nasal spray with a novel for the treatment to improve cognitive impairment caused by mental fatigue and potentially other disorders that is in Phase II clinical trial; and PH284, an odorless and tasteless synthetic investigational pherine nasal spray with a novel for the treatments of the loss of appetite associated with chronic disorders, such as cancer, heart disease, as well as cachexia that is in Phase II clinical trial. In addition, the company is developing an oral candidate, AV-101, an Oral NMDR glycine site antagonist for the treatment of depression and neurological disorders that is in phase I clinical trial. Further, its clinical-stage pipeline consists of intranasal product candidates from a new class of potential neuroscience therapies comprising pherines. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Organization
Vistagen Therapeutics
Employees
56
CEO
Mr. Shawn K. Singh J.D.
Industry
Health Technology

Management People of Vistagen Therapeutics

NameTitle
Mr. Shawn K. Singh J.D.
President, CEO & Director
Ms. Cynthia Lynn Anderson CPA
VP & Chief Financial Officer
Mr. Joshua S. Prince M.B.A.
Chief Operating Officer
Mr. Reid G. Adler Esq., J.D.
General Counsel
Mr. Mark Adrian McPartland
Senior Vice President of Investor Relations
Ms. Michelle Peters Wellington
Vice President of Communications
Ms. Elissa Cote
Chief Corporate Development Officer
Ms. Trisha Fitzmaurice
Senior Vice President of Human Resources
Dr. Allen Easley Cato III, M.D., Ph.D.
Senior Vice President of Development Operations
Dr. Mark J. Ginski Ph.D.
Senior VP and Head of Chemistry, Manufacturing & Controls

Important FAQs about investing in VTGN Stock from India :

Can Indians buy Vistagen Therapeutics shares?

Yes, Indians can invest in the Vistagen Therapeutics (VTGN) from India.

With INDmoney, you can buy Vistagen Therapeutics at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Vistagen Therapeutics at zero transaction cost.

How can I buy Vistagen Therapeutics shares from India?

It is very easy to buy Vistagen Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Vistagen Therapeutics (VTGN) be purchased?

Yes, you can buy fractional shares of Vistagen Therapeutics with INDmoney app.

What are the documents required to start investing in Vistagen Therapeutics stocks?

To start investing in Vistagen Therapeutics, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What is Vistagen Therapeutics share price today?

Vistagen Therapeutics share price today stands at $2.01, Open: $2.05 ; Previous Close: $1.97 ; High: $2.07 ; Low: $2.00 ; 52 Week High: $4.21 ; 52 Week Low: $1.90.

The stock opens at $2.05, after a closing price of $1.97. The stock reached a daily high of $2.07 and a low of $2.00, with a 52-week high of $4.21 and a 52-week low of $1.90.

What are today’s High and Low prices of Vistagen Therapeutics Stock (VTGN)?

Today’s highest price of Vistagen Therapeutics (VTGN) is $2.07.

Today’s lowest price of Vistagen Therapeutics (VTGN) is $2.00.

What is the 52 Week High and Low Range of Vistagen Therapeutics Stock (VTGN)?

  • 52 Week High

    $4.21

  • 52 Week Low

    $1.90

What are the historical returns of Vistagen Therapeutics (VTGN)?

  • 1 Month Returns

    -18.76%

  • 3 Months Returns

    -33.22%

  • 1 Year Returns

    -44.82%

  • 5 Years Returns

    -87.63%

What is today's market capitalisation of Vistagen Therapeutics?

Today's market capitalisation of Vistagen Therapeutics VTGN is 57.4M

Who is the Chief Executive Officer (CEO) of Vistagen Therapeutics ?

Mr. Shawn K. Singh J.D. is the current Chief Executive Officer (CEO) of Vistagen Therapeutics.